Cost-effectiveness of prevention program for type 2 diabetes mellitus in high risk patients in the Republic of Srpska, Bosnia and Herzegovina

被引:0
|
作者
Grujic-Vujmilovic, Dragana [1 ,2 ]
Veljkovic, Kristina [3 ]
Gavric, Zivana [1 ,2 ]
Popovic-Pejicic, Snjezana [4 ,5 ]
机构
[1] Univ Banja Luka, Fac Med, Dept Social Med, Banja Luka, Republic Of Srp, Bosnia & Herceg
[2] Publ Hlth Inst Republ Srpska, Dept Social Med, Banja Luka, Republic of Srp, Bosnia & Herceg
[3] Univ Ljubljana, Fac Comp & Informat Sci, Lab Cryptog & Comp Secur, Vecna Pot 113, Ljubljana 1000, Slovenia
[4] Univ Banja Luka, Fac Med, Dept Internal Med, Banja Luka, Republic Of Srp, Bosnia & Herceg
[5] Univ Clin Ctr Republ Srpska, Banja Luka, Republic Of Srp, Bosnia & Herceg
关键词
Cost-effectiveness; Markov chain model; FINDRISC; prevention; impaired glucose tolerance; type 2 diabetes mellitus; GLUCOSE-TOLERANCE; CARDIOVASCULAR EVENTS; SCREENING-PROGRAM; UTILITY VALUES; MORTALITY; DISEASE; FOOT; LIFE; COMPLICATIONS; PROGRESSION;
D O I
10.1080/19932820.2024.2437226
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Republic of Srpska (RS), as a part of the Western Balkans (WB) region, has a higher diabetes prevalence than the EU. This study aims to assess the cost-effectiveness of early treatment of high-risk patients with pre-diabetes and undiagnosed diabetes in our setting. We designed a Markov chain Monte Carlo (MCMC) model which reflects the current International Diabetes Federation (IDF) three-step plan for the prevention of T2DM in those at increased risk. The model captures the evolution of the disease in FINDRISC high-risk patients from normal glucose tolerance (NGT) to impaired fasting glucose (IFG) or impaired glucose tolerance (IGT) and then to T2DM and its complications. We developed two MCMC models, in order to follow the progression of the disease in high-risk cases, ie, when early treatment is undertaken or when it is not undertaken. The health costs and quality adjusted life years (QALY) were discounted at an annual rate of 3%. The key model parameters were varied in one-way and probabilistic sensitivity analysis. Early treatment resulted in increased life expectancy, postponement of the onset of diabetes and increased QALY for all patients. The discounted incremental cost-effectiveness-ratios (ICER) in NGT, IFG, IGT, and T2DM patients were -289.9, 9724.03, -1478.59 and 4084.67 <euro>. In high-risk IGT patients, ICER was the most favorable, being both a cost saving and QALY gaining, with the consistent results confirmed by the sensitivity analysis. The results recommend the acceptance of a new health policy of identifying IGT patients with the use of FINDRISC questionnaire and plasma glucose measurements; providing them with a lifestyle change program; and implementing intensive diabetes treatment, as their disease progresses. Our results are especially significant for the Western Balkan countries, since this was the first cost-effectiveness study of T2DM prevention in this region.
引用
收藏
页数:18
相关论文
共 50 条
  • [1] Development of a model to assess the cost-effectiveness of gestational diabetes mellitus screening and lifestyle change for the prevention of type 2 diabetes mellitus
    Lohse, Nicolai
    Marseille, Elliot
    Kahn, James G.
    INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2011, 115 : S20 - S25
  • [2] Cost-effectiveness analysis of voglibose for prevention of type 2 diabetes mellitus in Japanese patients with impaired glucose tolerance
    Ikeda, Shunya
    Kobayashi, Makoto
    Tajima, Naoko
    JOURNAL OF DIABETES INVESTIGATION, 2010, 1 (06) : 252 - 258
  • [3] Cost-Effectiveness Of Drug Compliance In Type 2 Diabetes Mellitus Patients
    Maciel, Olga
    Vera, Zully
    Marin, Gustavo H.
    Morinigo, Macarena
    Maidana, Mabel
    Mastroianni, Patricia
    RESEARCH JOURNAL OF PHARMACEUTICAL BIOLOGICAL AND CHEMICAL SCIENCES, 2018, 9 (05): : 1824 - 1829
  • [4] Incremental Cost-Effectiveness Ratios (ICERs) and Revised Metformin Cost-Effectiveness Conclusions in the Diabetes Prevention Program/ Diabetes Prevention Program Outcomes Study
    Alolayan, Sultan
    Eguale, Tewodros
    Segal, Alissa R.
    Doucette, Joanne
    Rittenhouse, Brian E.
    AMERICAN JOURNAL OF LIFESTYLE MEDICINE, 2025,
  • [5] Cost-effectiveness of Preventing Type-2-Diabetes mellitus in Germany
    Schaufler, T. M.
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2009, 14 (02): : 71 - 75
  • [6] Cost-effectiveness of the Da Qing diabetes prevention program: A modelling study
    Hu, Wanxia
    Xu, Wenhua
    Si, Lei
    Wang, Cuilian
    Jiang, Qicheng
    Wang, Lidan
    Cutler, Henry
    PLOS ONE, 2020, 15 (12):
  • [7] Cost-Effectiveness of Aliskiren in Type 2 Diabetes, Hypertension, and Albuminuria
    Delea, Thomas E.
    Sofrygin, Oleg
    Palmer, James L.
    Lau, Helen
    Munk, Veronica C.
    Sung, Jennifer
    Charney, Alan
    Parving, Hans-Henrik
    Sullivan, Sean D.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (10): : 2205 - 2213
  • [8] Cost-effectiveness of primary prevention of type 2 diabetes
    Icks, A.
    Chernyak, N.
    Klein, A.
    Brinks, R.
    Genz, J.
    Giani, G.
    DIABETOLOGE, 2011, 7 (02): : 92 - 98
  • [9] A systematic review of the cost-effectiveness of lifestyle modification as primary prevention intervention for diabetes mellitus type 2
    Radl, Katrin I.
    Ianuale, Carolina
    Boccia, Stefania
    EPIDEMIOLOGY BIOSTATISTICS AND PUBLIC HEALTH, 2013, 10 (02)
  • [10] Cost-effectiveness analysis of a digital Diabetes Prevention Program (dDPP) in prediabetic patients
    Park, Sooyeol
    Ward, Trevor
    Sudimack, Andrew
    Cox, Sam
    Ballreich, Jeromie
    JOURNAL OF TELEMEDICINE AND TELECARE, 2025, 31 (02) : 239 - 255